Canada
· Delayed Price · Currency is CAD RAMM Pharma Statistics
Total Valuation
RAMM Pharma has a market cap or net worth of CAD 1.79 million. The enterprise value is 1.17 million.
| Market Cap | 1.79M |
| Enterprise Value | 1.17M |
Important Dates
The last earnings date was Friday, February 28, 2025.
| Earnings Date | Feb 28, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
RAMM Pharma has 119.39 million shares outstanding. The number of shares has decreased by -1.36% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 119.39M |
| Shares Change (YoY) | -1.36% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 27.52% |
| Owned by Institutions (%) | n/a |
| Float | 86.54M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.41 |
| PB Ratio | 0.13 |
| P/TBV Ratio | 0.13 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -0.07 |
| EV / Sales | 0.27 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -0.29 |
Financial Position
The company has a current ratio of 1.77, with a Debt / Equity ratio of 0.01.
| Current Ratio | 1.77 |
| Quick Ratio | 0.81 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.05 |
| Interest Coverage | -202.31 |
Financial Efficiency
Return on equity (ROE) is -76.58% and return on invested capital (ROIC) is -25.57%.
| Return on Equity (ROE) | -76.58% |
| Return on Assets (ROA) | -22.78% |
| Return on Invested Capital (ROIC) | -25.57% |
| Return on Capital Employed (ROCE) | -65.15% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.18 |
| Inventory Turnover | 0.90 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -66.67% in the last 52 weeks. The beta is 0.22, so RAMM Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.22 |
| 52-Week Price Change | -66.67% |
| 50-Day Moving Average | 0.02 |
| 200-Day Moving Average | 0.02 |
| Relative Strength Index (RSI) | 36.92 |
| Average Volume (20 Days) | 25,218 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, RAMM Pharma had revenue of CAD 4.34 million and -16.50 million in losses. Loss per share was -0.14.
| Revenue | 4.34M |
| Gross Profit | 1.78M |
| Operating Income | -8.94M |
| Pretax Income | -16.49M |
| Net Income | -16.50M |
| EBITDA | -7.97M |
| EBIT | -8.94M |
| Loss Per Share | -0.14 |
Balance Sheet
The company has 814,040 in cash and 188,309 in debt, giving a net cash position of 625,731 or 0.01 per share.
| Cash & Cash Equivalents | 814,040 |
| Total Debt | 188,309 |
| Net Cash | 625,731 |
| Net Cash Per Share | 0.01 |
| Equity (Book Value) | 13.63M |
| Book Value Per Share | 0.11 |
| Working Capital | 2.33M |
Cash Flow
In the last 12 months, operating cash flow was -4.00 million and capital expenditures -47,431, giving a free cash flow of -4.05 million.
| Operating Cash Flow | -4.00M |
| Capital Expenditures | -47,431 |
| Free Cash Flow | -4.05M |
| FCF Per Share | -0.03 |
Margins
| Gross Margin | 40.92% |
| Operating Margin | -205.86% |
| Pretax Margin | -379.87% |
| Profit Margin | n/a |
| EBITDA Margin | -183.47% |
| EBIT Margin | -205.86% |
| FCF Margin | n/a |
Dividends & Yields
RAMM Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 1.36% |
| Shareholder Yield | 1.36% |
| Earnings Yield | -921.48% |
| FCF Yield | -225.89% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
RAMM Pharma has an Altman Z-Score of -5.84. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -5.84 |
| Piotroski F-Score | n/a |